The phase 3 CanStem111P study was terminated early due to futility.
Rucaparib was active in patients with germline BRCA2, germline PALB2, and somatic BRCA2 variants.
Non-White and non-Hispanic patients were underrepresented throughout the period studied.
Stereotactic body radiotherapy plus pembrolizumab and trametinib improved overall and progression-free survival.
The AACR COVID-19 and Cancer Task Force recommends keeping changes to clinical trial practices that were prompted by the pandemic.
A sequential treatment strategy was less effective than a maintenance strategy.
Nab-paclitaxel was associated with an improvement in long-term overall survival.
A statement recommends including cancer patients and survivors in COVID-19 vaccine trials.
GRASP co-founder Julia Maués explains how the initiative came about and reveals plans for the future.
Black cancer patients were 44% less likely than White patients to enroll in a portal that provides access to electronic health records.
The single-center study evaluated 119 consecutive patients with LAPC who underwent A-RT from 2016 to 2019.
A team of investigators sought to investigate the usefulness of contrast-enhanced harmonic ultrasound-guided fine needle aspiration/biopsy when performed with no on-site cytopathology.
SEQUOIA trial investigators compared pegilodecakin plus FOLFOX with FOLFOX alone in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).
Vitamin D is a biomarker of interest in the pancreatic cancer setting.
The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
Investigators compared the outcomes of patients who received pancreatic enzyme replacement therapy (PERT) with those who did not.
The ARC-8 study evaluated whether AB680, the anti-PD-1 antibody zimberelimab, and chemotherapy could improve metastatic pancreatic adenocarcinoma (PDAC) outcomes.
Preliminary data suggest that neoadjuvant treatment of resected pancreatic cancer with urelumab plus nivolumab and GVAX was well tolerated and showed some antitumor activity in a small study.
Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.
A recent HHS announcement spurred concern that FDA oversight of LDTs was eroding, threatening patient safety — but the reality is less dire.